IntelGenx Technologies Corp. Stock Toronto S.E.

Equities

IGX

US45822R1014

Pharmaceuticals

End-of-day quote Toronto S.E. 06:00:00 2021-10-17 pm EDT 5-day change 1st Jan Change
0.78 CAD +9.86% Intraday chart for IntelGenx Technologies Corp. +50.00% +173.68%
Sales 2022 950K 1.31M Sales 2023 1.04M 1.43M Capitalization 24.12M 33.26M
Net income 2022 -10M -13.79M Net income 2023 -9M -12.41M EV / Sales 2022 44.7 x
Net Debt 2022 7.98M 11.01M Net Debt 2023 13.22M 18.22M EV / Sales 2023 35.9 x
P/E ratio 2022
-2.82 x
P/E ratio 2023
-2.43 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 77.6%
More Fundamentals * Assessed data
Dynamic Chart
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial CI
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA MT
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA CI
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises MT
Transcript : IntelGenx Technologies Corp., Q4 2023 Earnings Call, Mar 21, 2024
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences MT
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences MT
IntelGenx Technologies Corp. announced that it expects to receive $2 million in funding CI
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million MT
IntelGenx Technologies Corp. announced that it expects to receive $20 million in funding CI
IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx?s VetaFilm® Platform in Healthy Dogs and Cats CI
IntelGenx, Covenant Animal Health Partners Unit Sign Development, License Pacts for VetaFilm MT
IntelGenx Corp. Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm CI
IntelGenx Brief: Announcing New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm MT
More news
Managers TitleAgeSince
Chief Executive Officer 66 23-04-12
Director of Finance/CFO 61 15-07-19
Chairman 77 06-03-31
Members of the board TitleAgeSince
Chairman 77 06-03-31
Director/Board Member 54 16-08-08
Director/Board Member 72 09-04-07
More insiders
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allows for pharmaceutical products that address unmet medical needs. It provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. Its product portfolio includes Migraine (Rizatriptan), Erectile Dysfunction (Tadalafil), Schizophrenia (Lozapine), Neurodegenerative, Opioid Dependence (Buprenorphine / Naloxone) and others.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.17
Average target price
-
Consensus